2016
DOI: 10.1108/amhid-10-2015-0051
|View full text |Cite
|
Sign up to set email alerts
|

Short communication: reliability and validity of the UKU Side Effect Rating Scale for adults with intellectual disabilities

Abstract: About Emerald www.emeraldinsight.comEmerald is a global publisher linking research and practice to the benefit of society. The company manages a portfolio of more than 290 journals and over 2,350 books and book series volumes, as well as providing an extensive range of online products and additional customer resources and services.Emerald is both COUNTER 4 and TRANSFER compliant. The organization is a partner of the Committee on Publication Ethics (COPE) and also works with Portico and the LOCKSS initiative fo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(7 citation statements)
references
References 12 publications
0
7
0
Order By: Relevance
“…Adams and Shah (2016) discussed the importance of recognising adverse effects in this population and the requirement for adverse effect rating scales for people with an intellectual disability. The Udvalg for Kliniske Undersøgelser, UKU (Lingjaerde et al, 1987) side effect rating scale has been adapted for adults with intellectual disabilities UKU-SERS-ID (Tveter et al, 2016), this validated tool that can be implemented into practice areas where adverse effect of psychotropic medications is of concern. It is vital that nurses working in forensic settings are adequately trained to report on the risks and benefits impact of the medications they are administering.…”
Section: Self-identified Clinical Training Need: the Environment And Behavioural Managementmentioning
confidence: 99%
“…Adams and Shah (2016) discussed the importance of recognising adverse effects in this population and the requirement for adverse effect rating scales for people with an intellectual disability. The Udvalg for Kliniske Undersøgelser, UKU (Lingjaerde et al, 1987) side effect rating scale has been adapted for adults with intellectual disabilities UKU-SERS-ID (Tveter et al, 2016), this validated tool that can be implemented into practice areas where adverse effect of psychotropic medications is of concern. It is vital that nurses working in forensic settings are adequately trained to report on the risks and benefits impact of the medications they are administering.…”
Section: Self-identified Clinical Training Need: the Environment And Behavioural Managementmentioning
confidence: 99%
“…One article describes a screening tool for detection of psychotropic side effects developed for patients with ID. This tool was developed at the Oslo University Hospital in Norway (Tveter et al, 2016). One article encompasses evaluations from the use of psychoeducational multi-family groups with patients with ID (Bakken et al, 2017).…”
Section: Resultsmentioning
confidence: 99%
“…There have been a number of projects addressing mental health in ID in Norway over the last two decades, and especially within the last decade, of which three examples will follow. First, a project on detecting side effects from psychotropic medication has been conducted by a regional department at the Oslo University Hospital (Tveter et al, 2016). This project is in its last phase, collecting data from patients with ID using psychotropic medication in both specialized mental health services, and in habilitation services (Tveter et al, 2016).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…These regular phone calls will be carried out every two days during the whole dose titration phase until the participant reaches a stable dose for the open-label phase. The study team will also check whether the participant shows any physical or mental changes believed to be attributed to adverse events based on the UKU side effect rating scale [68], and advise the participant and his/her/their caregivers accordingly on the next step of titration. Dose adjustments are performed until the participant reaches the maximum permitted dose of 1 mg twice daily or experiences intolerable adverse events believed to be related to nabilone.…”
Section: • Concomitant Medication(s)mentioning
confidence: 99%